AI Stock · 1 phase

CRSP — CRISPR Therapeutics

Live: $46.54 · YTD -13.4% · as of 2026-07-24

CRISPR Therapeutics (CRSP) appears in the Singularity Race 9-Phase AI Investment Framework in the phase below, each with its investment thesis.

Where CRSP fits

PhaseThesis
Phase 7 — AI Healthcare RevolutionCasgevy $116M FY2025 (from $0); $2.2M/patient; approved US/EU/UK/Canada; $1.8B+ cash; CTX320 cardio data H1 2026
Scan your portfolio →All stocksThe 9-phase map →

Educational framework, not financial advice. Tickers and theses are illustrative of each phase's investment thesis, not recommendations.